Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00RYU
|
|||
| Former ID |
DIB016907
|
|||
| Drug Name |
IPH-2102
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 2 | [1] | |
| Company |
Innate Pharma SA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | MHC class I NK cell receptor 2DL1 (CD158A) | Target Info | Antagonist | [2] |
| MHC class I NK cell receptor 2DL2 (CD158b1) | Target Info | Antagonist | [2] | |
| MHC class I NK cell receptor 2DL3 (CD158b2) | Target Info | Antagonist | [2] | |
| KEGG Pathway | Antigen processing and presentation | |||
| Natural killer cell mediated cytotoxicity | ||||
| Graft-versus-host disease | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| WikiPathways | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01687387) Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR). U.S. National Institutes of Health. | |||
| REF 2 | Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.